Bristol-Myers Squibb Company (NYSE: BMY) announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) in Phase 3 CheckMate -238 StudySeptember 11, 2017 6:21 AM Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 TrialSeptember 11, 2017 6:16 AM Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung CancerSeptember 8, 2017 5:49 AM CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell CarciSeptember 7, 2017 6:59 AM Bristol-Myers Squibb (BMY) Offers Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma on Partial Clinical HoldSeptember 6, 2017 5:26 PM